The 10 highest-cost drugs reimbursed by public drug plans in Canada in the 2021/22 fiscal year were all rare disease treatments with annual treatment costs of more than $250,000, according to a new report by the Patented Medicine Prices Review Board. It found the increased use of high-cost drugs continued to be the main factor […]
Half (51 per cent) of plan members say the coverage levels of at least one of their health benefits limit their ability to seek necessary treatment, jumping to 84 per cent among those with a major injury in the past 12 months, according to the 2023 Benefits Canada Healthcare Survey. It found this percentage increased […]
Latest CPP additions to cost $900 million by 2050, says Canada's chief actuary.